Campath-1H for Treating Adult T-Cell Leukemia/Lymphoma

• Sponsor: National Cancer Institute (NCI) (NIH)
• Overall Status: Completed
• CT.gov ID: NCT00061048
• Collaborator: (none)
• Enrollment: 29
• Location: 1
• Arm: 1
• Duration (Months): 110
• Patients Per Site Per Month: 0.3

Study Details

Study Description

Brief Summary

This study will examine the safety and effectiveness of Alemtuzumab (Campath-1H) for treating patients with adult T-cell leukemia/lymphoma (ATL). ATL is caused by a virus called human T-cell lymphotrophic virus type-1 (HTLV-1) that infects lymphocytes (white blood cells) called T-cells. Cancerous cells can be found not only in the blood, but also in the skin, lungs, lymph nodes, liver, bone, bone marrow, spleen, and meninges (tissues covering the brain). There are four categories of ATL, based on the aggressiveness of disease-smoldering, chronic, lymphoma, and acute. Campath-1H is a monoclonal antibody that attaches to and kills normal and cancerous lymphocytes, including T cells. Although Campath-1H is an experimental drug for treating ATL, it is approved by the Food and Drug Administration for treating chronic lymphocytic leukemia.

Patients 18 years of age and older with any type of ATL except smoldering may be eligible for this study. Candidates are screened with a medical history and physical examination, photos of skin lesions, measurement of lesions such as lymph nodes and skin nodules, blood and urine tests, electrocardiogram (EKG), chest x-ray, computed tomography (CT) scan or ultrasound of the abdomen, skin biopsy, bone marrow aspirate and biopsy, skin test, and lumbar puncture (spinal tap). Participants undergo treatment in two phases, as follows:

• Dose escalation phase: Patients receive an infusion of Campath-1H daily for three days. The initial dose is low and is increased daily as long as there are no side effects, or only mild reactions, until the patient is receiving the maximum dose of 30 milligrams per day.

• Stable dose phase: Patients receive infusions of Campath-1H 30 mg three times a week for up to 12 weeks.

In addition to treatment, patients are evaluated with the following tests and procedures:

• History and physical examination every 4 weeks.

• Blood tests every 4 weeks.

• CT scans to measure the size of the tumors every 4 weeks.

• Skin biopsies (if skin disease is present) and lymph note aspirates: Up to five biopsies and five aspirates may be taken to help diagnose the disease and evaluate the effect of Campath-1H on the cancer.

• Bone marrow biopsy: This procedure may be done to document or monitor disease progress.

Patients receive treatment for up to 12 weeks. Treatment may stop earlier if the patient achieves a complete response before the end of 12 weeks. Patients completing the study are followed periodically with a history and physical examination, blood and urine tests, tumor evaluation, skin biopsy and skin testing. They are seen monthly at first and then at 3-month intervals the first year; every 4 months the second year, every 6 months for the third through fifth years, and then yearly.

Condition or Disease	Intervention/Treatment	Phase
Acute T-Cell Leukemia-Lymphoma	Biological: Alemtuzumab	Phase 2

Detailed Description

Background:

Adult T-cell leukemia/lymphoma (ATL) is an aggressive lymphoproliferative disorder caused by an infection with the human T-cell lymphotrophic virus type-1 (HTLV-1).

ATL is characterized by rapidly rising peripheral blood leukemia cell counts, lymphadenopathy, lytic bone lesions, hepatosplenomegaly, and skin and solid organ involvement by tumor.

Chemotherapy has shown modest activity and the treatment of ATL has remained largely undefined and the survival of ATL patients poor.

The CD52 surface glycoantigen is overexpressed on ATL cells.

Alemtuzumab (Campath-1H) is a humanized rat monoclonal antibody that binds to CD52 and is cytotoxic.

In preclinical models, Campath-1H inhibited tumor growth and improved the survival of Non-obese diabetic (NOD)/severe combined immune deficiency (SCID) mice injected with human MET-1 ATL cells.

Objectives:

To determine the efficacy of Campath-1H in the treatment of ATL.

To define the time course of Campath-1H saturation in patients with ATL.

To define the toxicity of Campath-1H in patients with ATL.

Eligibility:

Patients with HTLV-I-associated adult T-cell leukemia.

More than 10% of the malignant cells must express CD52 and CD25.

Patients must have measurable disease.

The patient must have a granulocyte count of at least 1000/mm(3) and a platelet count of greater than or equal to 50,000/mm(3).

Design:

A single institution non-randomized open-label Phase II trial.

This trial will recruit a maximum of 30 eligible patients.

Patients will receive antimicrobial and antiviral prophylaxis while on-study due to the known immunosuppressive effects of Campath-1H.

Patients will receive I.V. Campath-1H 3 mg on day 1, 10 mg on day 2, and 30 mg day 3 followed by maintenance Campath-1H 30 mg I.V. three time per week.

Patients will be evaluated for response and continuation of Campath-1H therapy after weeks 4 and 8 of maintenance treatment.

Patients are eligible to receive a maximum of 12 weeks of maintenance Campath-1H treatment.

Study Design

• Study Type: Interventional
• Actual Enrollment: 29 participants
• Allocation: Non-Randomized
• Intervention Model: Single Group Assignment
• Masking: None (Open Label)
• Primary Purpose: Treatment
• Official Title: Phase II Study of the Efficacy and Toxicity of Campath-1H in the Therapy of Adult T-Cell Leukemia
• Study Start Date: May 1, 2003
• Actual Primary Completion Date: Jul 1, 2009
• Actual Study Completion Date: Jul 1, 2012

Arms and Interventions

Arm	Intervention/Treatment
Experimental: Campath-1H Infusion of Campath-1H 3 mg on day # 1, 10 mg on day #2, and 30 mg day # 3 followed by maintenance Campath-1H 30 mg intravenously three times per week.	Biological: Alemtuzumab; Infusion of Campath-1H 3 mg on day # 1, 10 mg on day #2, and 30 mg day # 3 followed by maintenance Campath-1H 30 mg intravenously three times per week. Patients are eligible to receive a maximum of 12 weeks of maintenance Campath-1H treatment.

Outcome Measures

Primary Outcome Measures

1. Overall Response Rate [60 months]

   Overall response rate is defined as the percentage of participants with response and utilizes the International Standardized workshop definition. Complete response(CR)-Complete disappearance of all detectable clinical and radiographic evidence of disease and disappearance of all disease related symptoms if present before therapy and normalization of those biochemical abnormalities (for example LDH) definitely assignable to the lymphoma. Please see the protocol Link module for the full criteria if desired.

2. Overall Survival [60 months]

   Time between the first day of treatment to the day of death.

3. Time to Progression [60 months]

   Time between the first day of treatment to the day of disease progression which is defined as a persistent (at least two determinations) doubling of the peripheral blood leukemic cell count, the development of new lesions, or Ca elevations that are uncontrolled by conventional therapeutic procedures.

Secondary Outcome Measures

1. Cell Surface Expression of CD52 on Tumor Cells [6 months]

   The CD52 antibody-binding capacity (ABC) value is the measurement of the mean value of the maximum capacity of each cell to bind the anti-CD52 and when determined under conditions of saturating levels of antibody measures number of mean surface CD52 antigens per cell. CD52 ABC is negative when 100% saturation by therapeutic antibody is achieved.

2. The Number of Participants With Adverse Events [18 months]

   Here are the total number of participants with adverse events. For the detailed list of adverse events see the adverse event module.

Eligibility Criteria

Criteria

• Ages Eligible for Study: 18 Years and Older
• Sexes Eligible for Study: All
• Accepts Healthy Volunteers: No

Inclusion Criteria:

• Patients must have serum antibodies directed to Human T-lymphotropic Virus Type 1 (HTLV-1).

• All patients must have a histologically confirmed diagnosis of adult T- cell leukemia/lymphoma and more than 10% of the malignant cells must express CD52 and CD25.

• All stages of Tac-expressing adult T-cell leukemia except smoldering are eligible: patients with chronic, lymphoma or acute Acute T-cell leukemia/lymphoma (ATL) are eligible.

• Patients must have measurable disease. All patients with greater than 10% abnormal (i.e. Tac homogeneous strongly expressing) peripheral blood mononuclear cell (PBMC)in the peripheral blood will be deemed to have measurable disease.

• The patient must have a granulocyte count of at least 100/mm(3) and a platelet count of greater than or equal to 50,000/mm(3).

• Patients must have a creatinine of less than 3.0 mg/dl.

• Omission of cytotoxic chemotherapy for ATL for 3 weeks prior to entry into the trial is required. However patients receiving a stable dose of corticosteroids for at least three to four weeks without evidence of tumor response will be eligible.

• Patients must have a life expectancy of greater than 2 months.

• Eligible patients must be greater than or equal to 18 years old. There is no upper age limit.

• Patients must have serum glutamic oxaloacetic transaminase (SGOT) and serum glutamic pyruvic transaminase (SGPT) value less than or equal to 2.5-fold greater than the upper limit of normal and bilirubin less than or equal to 3.0/dl. If a liver function test is judged to be elevated due to the underlying ATL, this parameter will be considered an unevaluable parameter for toxicity determinations.

• Patients must be able to understand and sign an Informed Consent form.

• All patients must use adequate contraception during participation in this trial and for three months after completing therapy.

Exclusion Criteria:

• Patients with symptomatic leukemic meningitis will be excluded. However patients that have both ATL and another HTLV-1-associated disease, tropical spastic paraparesis (TSP) will be included.

• Pregnant and nursing patients are not eligible for the study. Because the effects of CAMPATH-1H on the developing fetus are unknown pregnant women will be excluded. Breast-feeding in patients with HTLV-1 infection is contraindicated because of the risk of transmission of the virus to the child. In addition, CAMPATH-1H may be present in breast milk and produce adverse events in the breast-feeding child.

• Human immunodeficiency virus (HIV) positive patients are excluded from the study. CAMPATH-1H may produce a different pattern of toxicities in patients with HIV infection and in addition the depletion of T cells produced by CAMPATH-1H may have adverse effects on HIV positive individuals.

• Patients with smoldering ATL are excluded.

• Patients with previously received Campath-1GH are ineligible.

Contacts and Locations

Locations

	Site	City	State	Country	Postal Code
1	National Institutes of Health, National Cancer Institute	Bethesda	Maryland	United States	20892

Sponsors and Collaborators

• National Cancer Institute (NCI)

Investigators

• Principal Investigator: Thomas A Waldmann, M.D., NCI, NIH

Study Documents (Full-Text)

None provided.

More Information

Additional Information:

• MedlinePlus
• Drug Information Portal
• U.S FDA Resources
• Journal of Clinical Oncology
• Report of an International Workshop to Standardize Response Criteria for Non-Hodgkin's Lymphomas

Publications

• Catane R, Longo DL. Monoclonal antibodies for cancer therapy. Isr J Med Sci. 1988 Sep-Oct;24(9-10):471-6. Review.
• Dickman S. Antibodies stage a comeback in cancer treatment. Science. 1998 May 22;280(5367):1196-7.
• Köhler G, Milstein C. Continuous cultures of fused cells secreting antibody of predefined specificity. 1975. Biotechnology. 1992;24:524-6.

• ClinicalTrials.gov Identifier: NCT00061048
• Other Study ID Numbers: 030194; 03-C-0194; 030194; NCT00064155
• First Posted: May 21, 2003
• Last Update Posted: Oct 31, 2012
• Last Verified: Oct 1, 2012

• Keywords provided by , ,: Monoclonal Antibody; HTLV-1; CD52; Flow Cytometry; Antibody Saturation; Adult T-Cell Leukemia (ATL); ATL
• Additional relevant MeSH terms: Lymphoma; Leukemia; Leukemia, T-Cell; Leukemia-Lymphoma, Adult T-Cell; Precursor T-Cell Lymphoblastic Leukemia-Lymphoma; Alemtuzumab

Study Results

Participant Flow

Recruitment Details	Anticipate enrolling 10-12 patients per year into the Campath-1H trial. Thus, if the trial goes to completion (2nd stage)we anticipate enrolling the 29 patients in approximately 2.5 years.

Arm/Group Title	Campath-1H Treatment of Adult T-cell Leukemia (ATL)
Arm/Group Description	Intravenous Campath-1H 3 mg on day #1, 10mg on day #2, and 30mg on day #3 followed by maintenance Campath-1H 30 mg intravenously three times per week. Patients are eligible to receive a maximum of 12 weeks of maintenance Campath-1H treatment.
Period Title: Overall Study
STARTED	29
COMPLETED	7
NOT COMPLETED	22

Baseline Characteristics

Arm/Group Title	Campath-1H Treatment of Adult T-cell Leukemia (ATL)
Arm/Group Description	Intravenous Campath-1H 3 mg on day #1, 10mg on day #2, and 30mg on day #3 followed by maintenance Campath-1H 30 mg intravenously three times per week. Patients are eligible to receive a maximum of 12 weeks of maintenance Campath-1H treatment.
Overall Participants	29
Age (Count of Participants)
<=18 years	0 0%
Between 18 and 65 years	25 86.2%
>=65 years	4 13.8%
Age (years) [Mean (Standard Deviation) ]
Mean (Standard Deviation) [years]	52.54 (13.39)
Sex: Female, Male (Count of Participants)
Female	19 65.5%
Male	10 34.5%
Region of Enrollment (participants) [Number]
United States	29 100%

Outcome Measures

1. Primary Outcome

Title	Overall Response Rate
Description	Overall response rate is defined as the percentage of participants with response and utilizes the International Standardized workshop definition. Complete response(CR)-Complete disappearance of all detectable clinical and radiographic evidence of disease and disappearance of all disease related symptoms if present before therapy and normalization of those biochemical abnormalities (for example LDH) definitely assignable to the lymphoma. Please see the protocol Link module for the full criteria if desired.
Time Frame	60 months

Outcome Measure Data

Analysis Population Description

[Not Specified]

Arm/Group Title	Campath-1H Treatment of Adult T-cell Leukemia (ATL)
Arm/Group Description	Intravenous Campath-1H 3 mg on day #1, 10mg on day #2, and 30mg on day #3 followed by maintenance Campath-1H 30 mg intravenously three times per week. Patients are eligible to receive a maximum of 12 weeks of maintenance Campath-1H treatment.
Measure Participants	29
Number (95% Confidence Interval) [percentage of participants]	52 179.3%

2. Primary Outcome

Title	Overall Survival
Description	Time between the first day of treatment to the day of death.
Time Frame	60 months

Outcome Measure Data

Analysis Population Description

[Not Specified]

Arm/Group Title	Campath-1H Treatment of Adult T-cell Leukemia (ATL)
Arm/Group Description	Intravenous Campath-1H 3 mg on day #1, 10mg on day #2, and 30mg on day #3 followed by maintenance Campath-1H 30 mg intravenously three times per week. Patients are eligible to receive a maximum of 12 weeks of maintenance Campath-1H treatment.
Measure Participants	29
Median (95% Confidence Interval) [months]	5.9

3. Primary Outcome

Title	Time to Progression
Description	Time between the first day of treatment to the day of disease progression which is defined as a persistent (at least two determinations) doubling of the peripheral blood leukemic cell count, the development of new lesions, or Ca elevations that are uncontrolled by conventional therapeutic procedures.
Time Frame	60 months

Outcome Measure Data

Analysis Population Description

[Not Specified]

Arm/Group Title	Campath-1H Treatment of Adult T-cell Leukemia (ATL)
Arm/Group Description	Intravenous Campath-1H 3 mg on day #1, 10mg on day #2, and 30mg on day #3 followed by maintenance Campath-1H 30 mg intravenously three times per week. Patients are eligible to receive a maximum of 12 weeks of maintenance Campath-1H treatment.
Measure Participants	29
Median (95% Confidence Interval) [months]	2.0

4. Secondary Outcome

Title	Cell Surface Expression of CD52 on Tumor Cells
Description	The CD52 antibody-binding capacity (ABC) value is the measurement of the mean value of the maximum capacity of each cell to bind the anti-CD52 and when determined under conditions of saturating levels of antibody measures number of mean surface CD52 antigens per cell. CD52 ABC is negative when 100% saturation by therapeutic antibody is achieved.
Time Frame	6 months

Outcome Measure Data

Analysis Population Description

[Not Specified]

Arm/Group Title	Campath-1H Treatment of Adult T-cell Leukemia (ATL)
Arm/Group Description	Intravenous Campath-1H 3 mg on day #1, 10mg on day #2, and 30mg on day #3 followed by maintenance Campath-1H 30 mg intravenously three times per week. Patients are eligible to receive a maximum of 12 weeks of maintenance Campath-1H treatment.
Measure Participants	29
Mean (Standard Deviation) [ABC value]	82.15 (13.7)

5. Secondary Outcome

Title	The Number of Participants With Adverse Events
Description	Here are the total number of participants with adverse events. For the detailed list of adverse events see the adverse event module.
Time Frame	18 months

Outcome Measure Data

Analysis Population Description

[Not Specified]

Arm/Group Title	Campath-1H Treatment of Adult T-cell Leukemia (ATL)
Arm/Group Description	Intravenous Campath-1H 3 mg on day #1, 10mg on day #2, and 30mg on day #3 followed by maintenance Campath-1H 30 mg intravenously three times per week. Patients are eligible to receive a maximum of 12 weeks of maintenance Campath-1H treatment.
Measure Participants	29
Number [participants]	8 27.6%

Adverse Events

Time Frame	5 years
Arm/Group Title	Campath-1H Treatment of Adult T-cell Leukemia (ATL)
Arm/Group Description	Intravenous Campath-1H 3 mg on day #1, 10mg on day #2, and 30mg on day #3 followed by maintenance Campath-1H 30 mg intravenously three times per week. Patients are eligible to receive a maximum of 12 weeks of maintenance Campath-1H treatment.
All Cause Mortality
	Campath-1H Treatment of Adult T-cell Leukemia (ATL)
	Affected / at Risk (%)	# Events
Total	/ (NaN)
Serious Adverse Events
	Campath-1H Treatment of Adult T-cell Leukemia (ATL)
	Affected / at Risk (%)	# Events
Total	8/29 (27.6%)
Endocrine disorders
ENDOCRINE:: Endocrine-Other (Endocrine:hyperthyroidism graves disease)	1/29 (3.4%)	1
Eye disorders
OCULAR/VISUAL:: Vision-blurred vision	1/29 (3.4%)	1
Gastrointestinal disorders
GASTROINTESTINAL:: Vomiting	1/29 (3.4%)	1
General disorders
CONSTITUTIONAL SYMPTOMS:: Constitutional Symptoms-Other (death)	2/29 (6.9%)	2
CONSTITUTIONAL SYMPTOMS:: Fatigue (lethargy, malaise, asthenia)	1/29 (3.4%)	1
CONSTITUTIONAL SYMPTOMS:: Rigors, chills	1/29 (3.4%)	1
Infections and infestations
INFECTION/FEBRILE NEUTROPENIA:: Infection without neutropenia	1/29 (3.4%)	1
Metabolism and nutrition disorders
METABOLIC/LABORATORY:: Hypercalcemia	1/29 (3.4%)	1
Nervous system disorders
NEUROLOGY:: Neurology-Other (Unresponsiveness)	1/29 (3.4%)	1
Respiratory, thoracic and mediastinal disorders
PULMONARY:: Apnea	1/29 (3.4%)	1
PULMONARY:: Hypoxia	1/29 (3.4%)	1
Vascular disorders
CARDIOVASCULAR (GENERAL):: Hypotension	1/29 (3.4%)	1
Other (Not Including Serious) Adverse Events
	Campath-1H Treatment of Adult T-cell Leukemia (ATL)
	Affected / at Risk (%)	# Events
Total	29/29 (100%)
Blood and lymphatic system disorders
HEMORRHAGE:: Epistaxis	7/29 (24.1%)	7
HEMORRHAGE:: Vaginal bleeding	1/29 (3.4%)	1
INFECTION/FEBRILE NEUTROPENIA:: Catheter-related infection	1/29 (3.4%)	1
INFECTION/FEBRILE NEUTROPENIA:: Febrile neutropenia (fever of unknown origin without clinically or m	1/29 (3.4%)	1
INFECTION/FEBRILE NEUTROPENIA:: Infection (documented clinically or microbiologically) with grade 3	1/29 (3.4%)	1
INFECTION/FEBRILE NEUTROPENIA:: Infection without neutropenia	9/29 (31%)	17
INFECTION/FEBRILE NEUTROPENIA:: Infection/Febrile Neutropenia-Other (CMV antigenemia)	5/29 (17.2%)	5
LYMPHATICS:: Lymphatics	1/29 (3.4%)	1
LYMPHATICS:: Lymphatics-Other (Lymphocytes)	1/29 (3.4%)	1
Cardiac disorders
CARDIOVASCULAR (ARRHYTHMIA):: Cardiovascular/Arrhythmia-Other (irregular heartbeat))	1/29 (3.4%)	1
CARDIOVASCULAR (ARRHYTHMIA):: Sinus bradycardia	1/29 (3.4%)	2
CARDIOVASCULAR (ARRHYTHMIA):: Sinus tachycardia	5/29 (17.2%)	13
CARDIOVASCULAR (ARRHYTHMIA):: Vasovagal episode	3/29 (10.3%)	3
CARDIOVASCULAR (GENERAL):: Edema	5/29 (17.2%)	7
CARDIOVASCULAR (GENERAL):: Phlebitis (superficial)	2/29 (6.9%)	2
Ear and labyrinth disorders
PAIN:: Earache (otalgia)	1/29 (3.4%)	1
Endocrine disorders
ENDOCRINE:: Hypothyroidism	1/29 (3.4%)	2
Eye disorders
OCULAR/VISUAL:: Dry eye	1/29 (3.4%)	1
OCULAR/VISUAL:: Ocular/Visual-Other (Ocular other: uveitis)	1/29 (3.4%)	1
OCULAR/VISUAL:: Tearing (watery eyes)	1/29 (3.4%)	1
OCULAR/VISUAL:: Vision-double vision (diplopia)	2/29 (6.9%)	2
OCULAR/VISUAL:: Vision-photophobia	1/29 (3.4%)	1
Gastrointestinal disorders
GASTROINTESTINAL:: Anorexia	6/29 (20.7%)	6
GASTROINTESTINAL:: Constipation	9/29 (31%)	13
GASTROINTESTINAL:: Diarrhea patients without colostomy	10/29 (34.5%)	11
GASTROINTESTINAL:: Dyspepsia/heartburn	3/29 (10.3%)	3
GASTROINTESTINAL:: Dysphagia, esophagitis, odynophagia (painful swallowing)	1/29 (3.4%)	1
GASTROINTESTINAL:: Flatulence	1/29 (3.4%)	1
GASTROINTESTINAL:: Gastrointestinal-Other (Abdominal distention)	1/29 (3.4%)	1
GASTROINTESTINAL:: Mouth dryness	1/29 (3.4%)	1
GASTROINTESTINAL:: Nausea	11/29 (37.9%)	13
GASTROINTESTINAL:: Stomatitis/pharyngitis (oral/pharyngeal mucositis)	3/29 (10.3%)	5
GASTROINTESTINAL:: Vomiting	10/29 (34.5%)	12
OCULAR/VISUAL:: Vision-blurred vision	2/29 (6.9%)	2
PAIN:: Abdominal pain or cramping	2/29 (6.9%)	2
General disorders
CONSTITUTIONAL SYMPTOMS:: Fatigue (lethargy, malaise, asthenia)	5/29 (17.2%)	6
CONSTITUTIONAL SYMPTOMS:: Fever (in the absence of neutropenia, where neutropenia is defined as AGC<	22/29 (75.9%)	68
CONSTITUTIONAL SYMPTOMS:: Rigors, chills	25/29 (86.2%)	48
CONSTITUTIONAL SYMPTOMS:: Sweating (diaphoresis)	1/29 (3.4%)	1
CONSTITUTIONAL SYMPTOMS:: Weight gain	1/29 (3.4%)	1
CONSTITUTIONAL SYMPTOMS:: Weight loss	3/29 (10.3%)	6
PAIN:: Chest pain (non-cardiac and non-pleuritic)	4/29 (13.8%)	4
Hepatobiliary disorders
HEPATIC:: Alkaline phosphatase	8/29 (27.6%)	10
HEPATIC:: Bilirubin	5/29 (17.2%)	11
HEPATIC:: GGT (Gamma-Glutamyl transpeptidase)	1/29 (3.4%)	1
HEPATIC:: Hypoalbuminemia	14/29 (48.3%)	38
HEPATIC:: SGOT (AST) (serum glutamic oxaloacetic transaminase)	12/29 (41.4%)	22
HEPATIC:: SGPT (ALT) (serum glutamic pyruvic transaminase)	9/29 (31%)	14
Immune system disorders
ALLERGY/IMMUNOLOGY:: Allergic reaction/hypersensitivity (including drug fever)	2/29 (6.9%)	2
ALLERGY/IMMUNOLOGY:: Allergic rhinitis (including sneezing, nasal stuffiness, postnasal drip)	2/29 (6.9%)	2
Investigations
BLOOD/BONE MARROW:: Hemoglobin	20/29 (69%)	81
BLOOD/BONE MARROW:: Leukocytes (total WBC)	15/29 (51.7%)	106
BLOOD/BONE MARROW:: Lymphopenia	18/29 (62.1%)	26
BLOOD/BONE MARROW:: Neutrophils/granulocytes (ANC/AGC)	11/29 (37.9%)	54
BLOOD/BONE MARROW:: Platelets	16/29 (55.2%)	41
COAGULATION:: Partial thromboplastin time (PTT)	4/29 (13.8%)	5
COAGULATION:: Prothrombin time (PT)	2/29 (6.9%)	2
METABOLIC/LABORATORY:: Amylase	2/29 (6.9%)	3
METABOLIC/LABORATORY:: Bicarbonate	2/29 (6.9%)	2
METABOLIC/LABORATORY:: CPK (creatine phosphokinase)	2/29 (6.9%)	2
METABOLIC/LABORATORY:: Hypercalcemia	5/29 (17.2%)	14
METABOLIC/LABORATORY:: Hypercholesterolemia	1/29 (3.4%)	1
METABOLIC/LABORATORY:: Hyperglycemia	13/29 (44.8%)	34
METABOLIC/LABORATORY:: Hyperkalemia	1/29 (3.4%)	3
METABOLIC/LABORATORY:: Hypermagnesemia	7/29 (24.1%)	12
METABOLIC/LABORATORY:: Hypernatremia	1/29 (3.4%)	1
METABOLIC/LABORATORY:: Hyperuricemia	6/29 (20.7%)	12
METABOLIC/LABORATORY:: Hypocalcemia	5/29 (17.2%)	20
METABOLIC/LABORATORY:: Hypoglycemia	4/29 (13.8%)	4
METABOLIC/LABORATORY:: Hypokalemia	9/29 (31%)	18
METABOLIC/LABORATORY:: Hypomagnesemia	9/29 (31%)	33
METABOLIC/LABORATORY:: Hyponatremia	10/29 (34.5%)	27
METABOLIC/LABORATORY:: Hypophosphatemia	6/29 (20.7%)	19
METABOLIC/LABORATORY:: Lipase	1/29 (3.4%)	1
METABOLIC/LABORATORY:: Metabolic/Laboratory-Other (Lactate)	1/29 (3.4%)	1
Musculoskeletal and connective tissue disorders
PAIN:: Arthralgia (joint pain)	3/29 (10.3%)	3
PAIN:: Bone pain	2/29 (6.9%)	2
PAIN:: Myalgia (muscle pain)	7/29 (24.1%)	13
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
PAIN:: Tumor pain (onset or exacerbation of tumor pain due to treatment)	1/29 (3.4%)	1
Nervous system disorders
NEUROLOGY:: Dizziness/lightheadedness	4/29 (13.8%)	4
NEUROLOGY:: Neuropathy - cranial	1/29 (3.4%)	1
NEUROLOGY:: Neuropathy - motor	3/29 (10.3%)	3
PAIN:: Headache	7/29 (24.1%)	11
PAIN:: Pain-Other (Dental-anterior pillars tender;Foot, sharp and intermittent;Right eye ache)	6/29 (20.7%)	7
Psychiatric disorders
NEUROLOGY:: Insomnia	5/29 (17.2%)	5
NEUROLOGY:: Mood alteration-anxiety, agitation	1/29 (3.4%)	1
NEUROLOGY:: Mood alteration-depression	1/29 (3.4%)	1
Renal and urinary disorders
RENAL/GENITOURINARY:: Creatinine	3/29 (10.3%)	5
RENAL/GENITOURINARY:: Hemoglobinuria	1/29 (3.4%)	1
RENAL/GENITOURINARY:: Proteinuria	3/29 (10.3%)	4
RENAL/GENITOURINARY:: Renal/Genitourinary-Other (Urine positive for white blood cells)	2/29 (6.9%)	2
Reproductive system and breast disorders
PAIN:: Pelvic pain	1/29 (3.4%)	1
Respiratory, thoracic and mediastinal disorders
PULMONARY:: Cough	5/29 (17.2%)	7
PULMONARY:: Dyspnea (shortness of breath)	3/29 (10.3%)	3
PULMONARY:: Hypoxia	2/29 (6.9%)	5
PULMONARY:: Pneumonitis/pulmonary infiltrates	1/29 (3.4%)	1
PULMONARY:: Pneumothorax	1/29 (3.4%)	1
Skin and subcutaneous tissue disorders
DERMATOLOGY/SKIN:: Bruising (in absence of grade 3 or 4 thrombocytopenia)	1/29 (3.4%)	2
DERMATOLOGY/SKIN:: Dry skin	3/29 (10.3%)	3
DERMATOLOGY/SKIN:: Injection site reaction	1/29 (3.4%)	1
DERMATOLOGY/SKIN:: Pruritus	8/29 (27.6%)	10
DERMATOLOGY/SKIN:: Rash/desquamation	8/29 (27.6%)	12
DERMATOLOGY/SKIN:: Urticaria (hives, welts, wheals)	11/29 (37.9%)	15
DERMATOLOGY/SKIN::Dermatology/Skin-Other(Thumb swelling)	1/29 (3.4%)	1
Vascular disorders
CARDIOVASCULAR (GENERAL):: Hypertension	2/29 (6.9%)	2
CARDIOVASCULAR (GENERAL):: Hypotension	11/29 (37.9%)	15

Limitations/Caveats

[Not Specified]

More Information

Certain Agreements

Principal Investigators are NOT employed by the organization sponsoring the study.

There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed.